This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.


A new era: expanding use of continuous glucose monitoring in type 2 diabetes

Discussion: what does the future hold?

How once-weekly insulin* could simplify diabetes treatment

How could once-weekly insulin* break down barriers in clinical practice

Discussion: what does the future hold?



*Novo Nordisk once-weekly insulin is not currently approved for diabetes treatment by the European Medicines Agency. Once-weekly insulins are in development and not available in any market.

Julia Mader, MD - Speaker

Julia Mader

Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria

Julia Mader is Associate Professor of Medicine at the Division of Endocrinology and Diabetology at the Medical University of Graz, Graz, Austria and is Deputy Head of the Diabetes Outpatient Clinic. She received her medical degree at the Medical University of Graz, where she also trained in Internal Medicine, and Endocrinology and Diabetology. From 2016 to 2017, Prof. Mader was Visiting Professor at the Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism at the University Hospital of Bern, Bern, Switzerland. She leads the Diabetes Technology Research Unit at the Medical University of Graz.


Prof. Mader’s research is focused on diabetes technology with an emphasis on insulin pumps, continuous glucose monitoring, the artificial pancreas and decision support systems. She has published more than 100 peer-reviewed scientific papers and serves as Associate Editor for Frontiers in Clinical Diabetes and Healthcare. Prof. Mader has received several awards in the field of diabetes technology, including the Langerhans award from the Austrian Diabetes Association in 2021. She is a member of several European associations and societies and is a management board member of the Austrian Diabetes Society, within which she heads the Diabetes Education Committee and is a member of the Diabetes Technology Committee. She has authored and co-authored several national guidelines in the field. 

Read full bio